Chronic Obstructive Pulmonary Disease
Conditions
Brief summary
Chronic obstructive pulmonary disease (COPD) is a frequent airway disease characterized by both bronchial inflammation and remodelling. Bronchial mucosa is infiltrated by macrophages, neutrophils and lymphocytes. In addition, the number of eosinophils can be also increased during exacerbation. Airway remodelling is an abnormal tissue repair following bronchial inflammation, which contributes to none reversible pathological features, such as bronchial and peri-bronchial fibrosis. It also influences the prognosis of COPD and its mechanisms remain largely unknown. The role of fibrocytes has been demonstrated in the pathophysiology of asthma, lung fibrosis or pulmonary hypertension. However, the recruitment of blood fibrocytes and their involvement in COPD airway remodelling remain unknown.
Interventions
PROCEDUREblood sample
blood sample for fibrocytes analysis
PROCEDUREClinical and functional evaluation
Plethysmography, Carbon monoxide capacity of transfer , arterial gaz
Sponsors
University Hospital, Bordeaux
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Patients: diagnostic of Chronic obstructive pulmonary disease (COPD) exacerbation. * Control group: subjects without any history of lung disease and with normal lung function testing. Subjects will be separated in 2 sub-groups according to smoking history (Never smokers, smokers (former or current) and paired to patients according to age and sex. * Written informed consent
Exclusion criteria
* Subject without any social security or health insurance * Asthma, lung fibrosis or idiopathic pulmonary hypertension * Chronic viral infections (hepatitis, HIV)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of circulating blood fibrocytes | Day 1 | Sampling of blood in Chronic obstructive pulmonary disease patients |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Characterization of fibrocytes | Day 1 and at 2 months | Sampling of blood |
| Differenciation of blood fibrocytes | Day 1 and at 2 months | Sampling of blood |
| Chemotactism of blood fibrocytes | Day 1 and at 2 months | Sampling of blood |
| Number of exacerbation | 12 months after V2 | — |
| Mortality | 12 months after V2 | — |
| Annual decline of ventilatory function | 12 months after V2 | — |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORPatrick BERGER, PUPH
University Hospital Bordeaux (France)
Outcome results
None listed